Trends in the epidemiology and care of diabetes mellitus-related end-stage renal disease in France, 2007-2011

Diabetologia

Volumn 57, Issue 4, 2014, Pages 718-728

  Assogba, Frank G A ^a,b   Couchoud, Cécile ^a   Hannedouche, Thierry ^c   Villar, Emmanuel ^d,e   Frimat, Luc ^f   Fagot Campagna, Anne ^g   Jacquelinet, Christian ^a   Stengel, Bénédicte ^h,i  

^a AGENCE DE LA BIOMÉDECINE   (France)

^b French Institute for Public Health Surveillance   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d CENTRE HOSPITALIER SAINT JOSEPH SAINT LUC   (France)

^e UNIVERSITÉ LYON 1   (France)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

^g Department of Studies on Diseases and Patients French National Health Insurance Fund for Salaried Workers   (France)

^h CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

ⁱ UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Care; Diabetes mellitus; End stage renal disease; Epidemiology; Incidence; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Indexed keywords

ADULT; AGED; AGING; ARTICLE; DIABETES MELLITUS; DIALYSIS; END STAGE RENAL DISEASE; FEMALE; FRANCE; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; POPULATION GROWTH; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; FRANCE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED;

EID: 84896066102     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3160-9     Document Type: Article

References (40)

1. Kramer A, Stel V, Zoccali C et al (2009) An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. Nephrol Dial Transplant 24:3557-3566
2. Grace BS, Clayton P, McDonald SP (2012) Increases in renal replacement therapy in Australia and New Zealand: understanding trends in diabetic nephropathy. Nephrology (Carlton) 17:76-84
3. Foley RN, Collins AJ (2007) End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 18:2644-2648 (Pubitemid 47531190)
4. US Renal Data System (2012) USRDS 2012 annual data report: atlas of end-stage renal disease in the United States. Available from www.usrds.org/2012/view/default.aspx, accessed 18 July 2013
5. Canadian Institute for Health Information (2011) Annual report: treatment of end-stage organ failure in Canada, 2001 to 2010. Available from https://www.secure.cihi.ca/free-products/2011-CORR-Annua-Report-EN.pdf, accessed 18 July 2013
6. Hill CJ, Fogarty DG (2012) Changing trends in end-stage renal disease due to diabetes in the United Kingdom. J Ren Care 38(Suppl 1):12-22
7. Sorensen VR, Hansen PM, Heaf J, Feldt-Rasmussen B (2006) Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark. Kidney Int 70:187-191 (Pubitemid 44000137)
8. Renal Epidemiology and Information Network (2012) 2010 Annual report. Nephrol Ther 5(Suppl 1):S169-S218
9. Blotiere PO, Tuppin P, Weill A, Ricordeau P, Allemand H (2010) The cost of dialysis and kidney transplantation in France in 2007; impact of an increase of peritoneal dialysis and transplantation. Nephrol Ther 6:240-247, article in French
10. Assogba GF, Couchoud C, Roudier C et al (2012) Prevalence, screening and treatment of chronic kidney disease in people with type 2 diabetes in France: the ENTRED surveys (2001 and 2007). Diabetes Metab 38:558-566
11. Bonnet F, Gauthier E, Gin H et al (2011) Expert consensus on management of diabetic patients with impairment of renal function. Diabetes Metab 37(Suppl 2):S1-S25
12. Ricci P, Blotière PO, Weill A, Simon D, Ricordeau P, Allemand H (2010) Treated diabetes: which trends between 2000 and 2009 in France? Bull Epidémiol Hebd 43:425-431
13. National Agency for Accreditation and Evaluation in Health Care (2002) Diagnosis of end-stage renal disease in adults. Available from www.has-sante.fr/portail/upload/docs/application/pdf/irc-chez-ladulte-2002-- recommandations.pdf, accessed 18 July 2013
14. Villar E, Chang SH, McDonald SP (2007) Incidences, treatments, outcomes, and sex effect on survival in patients with end-stage renal disease by diabetes status in Australia and New Zealand (1991-2005). Diabetes Care 30:3070-3076 (Pubitemid 350255248)
15. Couchoud C, Stengel B, Landais P et al (2006) The renal epidemiology and information network (REIN): a new registry for end-stage renal disease in France. Nephrol Dial Transplant 21:411-418 (Pubitemid 43159996)
16. van Dijk PC, Jager KJ, de Charro F (2001) Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 16:1120-1129 (Pubitemid 32547364)
17. Bashir S, Esteve J (2000) Analysing the difference due to risk and demographic factors for incidence or mortality. Int J Epidemiol 29: 878-884
18. Locatelli F, Aljama P, Canaud B et al (2010) Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) study. Nephrol Dial Transplant 25:2846-2850
19. U.S. Renal Data System (2013) USRDS 2013 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda
20. Couchoud C, Guihenneuc C, Bayer F, Lemaitre V, Brunet P, Stengel B (2012) Medical practice patterns and socio-economic factors may explain geographical variation of end-stage renal disease incidence. Nephrol Dial Transplant 27:2312-2322
21. Ward MM (2009) Access to care and the incidence of end-stage renal disease due to diabetes. Diabetes Care 32:1032-1036
22. Hsu CY, Vittinghoff E, Lin F, Shlipak MG (2004) The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 141:95-101
23. Locatelli F, Pozzoni P, Del Vecchio L (2004) Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol 15(Suppl 1):S25-S29 (Pubitemid 38018450)
24. van Dijk PC, Jager KJ, Stengel B, Gronhagen-Riska C, Feest TG, Briggs JD (2005) Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int 67:1489-1499 (Pubitemid 40463126)
25. Couchoud C, Guihenneuc C, Bayer F, Stengel B (2010) The timing of dialysis initiation affects the incidence of renal replacement therapy. Nephrol Dial Transplant 25:1576-1578
26. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS (2009) Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 122:443-453
27. Saaddine JB, Cadwell B, Gregg EW et al (2006) Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 144:465-474 (Pubitemid 46780669)
28. Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860
29. Imperatore G, Cadwell BL, Geiss L et al (2004) Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971-2000. Am J Epidemiol 160:531-539 (Pubitemid 39215629)
30. Fagot-Campagna A, Fosse S, Roudier C et al (2009) Characteristics, vascular risk and complications in people with diabetes, in metropolitan France: major improvements between ENTRED 2001 and ENTRED 2007 studies. Bull Epidémiol Hebd 42-43:450-455
31. Pan XR, Li GW, Hu YH et al (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544
32. Brenner BM, Cooper ME, de Zeeuw D (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869
33. McClellan WM, Flanders WD (2003) Risk factors for progressive chronic kidney disease. J Am Soc Nephrol 14(Suppl 2):S65-S70 (Pubitemid 36750495)
34. Bayat S, Frimat L, Thilly N, Loos C, Briancon S, Kessler M (2006) Medical and non-medical determinants of access to renal transplant waiting list in a French community-based network of care. Nephrol Dial Transplant 21:2900-2907 (Pubitemid 44542248)
35. Lassalle M, Labeeuw M, Frimat L et al (2010) Age and comorbidity may explain the paradoxical association of an early dialysis start with poor survival. Kidney Int 77:700-707
36. Ritz E (2005) Managing anaemia and diabetes: a future challenge for nephrologists. Nephrol Dial Transplant 20(Suppl 6):vi21-vi25
37. Thomas MC, Cooper ME, Tsalamandris C, MacIsaac R, Jerums G (2005) Anemia with impaired erythropoietin response in diabetic patients. Arch Intern Med 165:466-469 (Pubitemid 40280206)
38. Thilly N, Stengel B, Boini S, Villar E, Couchoud C, Frimat L (2008) Evaluation and determinants of underprescription of erythropoiesis stimulating agents in pre-dialysis patients with anaemia. Nephron Clin Pract 108:c67-c74 (Pubitemid 351253447)
39. Kilpatrick RD, Critchlow CW, Fishbane S et al (2008) Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 3:1077-1083
40. Szczech LA, Barnhart HX, Inrig JK et al (2008) Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74:791-798